An observational study in Dyslipidemias, sponsored by Daewoong Pharmaceutical Co. LTD.. Active, not recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-08-24.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Observational
This observation study is to evaluate blood lipid-lowering effects and liver/renal safety, changes in HbA1c and FPG in patients with dyslipidemia who administered CREZET tablets for 24 weeks.
A subject who is diagnosed with dyslipidemia and scheduled to administer CREZET tablets, will be enrolled in this study based on the doctor's medical decision.
The CREZET Tablet will be administered for 24 weeks, and the data including demographic information, body measurement, vital signs and etc will be collected during the study period.
The data collection point is as follows.
1,073 studies on the registry are indexed under Dyslipidemias; 158 are open to participants now.
This study's planned enrollment of 15,000 is above the median of 600 across 204 observational studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 196 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The number of test subjects was calculated using the confidence interval of the rate of change, noting that the primary purpose of this observation study was to evaluate the rate of change in a single group.
Recruitment of 14,151 people, which is 1.5%, was expected by referring to the minimum number of subjects required and the estimated patients taking two components of single drug and ezetimib compound.
However, this study was a non-intervention observation study conducted under daily treatment, and it was confirmed that the number of subjects who applied 10% of the dropout rate was about 15,000 Therefore, this study will be conducted with study population of 15,000 subjects.
Exclusion Criteria:
A person who is prohibited from administering according to the permission of the Crezet definition
Drug: Ezetimibe/Rosuvastatin
Patient treated with Crezet Tablet
Also known as: Crezet Tablet
The Rate of change in LDL-C
The Rate of change in LDL-C at 24 weeks from baseline
Time frame: 24 weeks
The Rate of change in LDL-C
The Rate of change in LDL-C at 12 weeks from baseline
Time frame: 12 weeks
The change in HbA1c
The change in HbA1c at 12 weeks from baseline
Time frame: 12 weeks
The change in HbA1c
The change in HbA1c at 24 weeks from baseline
Time frame: 24 weeks
The change in FPG
The change in FPG at 12 weeks from baseline
Time frame: 12 weeks
The change in FPG
The change in FPG at 24 weeks from baseline
Time frame: 24 weeks
The chanage in lipid variable
The chanage in lipid variable at 12 weeks from baseline
Time frame: 12 weeks
The chanage in lipid variable
The chanage in lipid variable at 24 weeks from baseline
Time frame: 24 weeks
The change in AST
The change in AST at 12 weeks from baseline
Time frame: 12 weeks
The change in AST
The change in AST at 24 weeks from baseline
Time frame: 24 weeks
The change in ALT
The change in ALT at 12 weeks from baseline
Time frame: 12 weeks
The change in ALT
The change in ALT at 24 weeks from baseline
Time frame: 24 weeks
Percentage of subjects who reached LDL-C target
Percentage of subjects who reached LDL-C target according to Korean Society of Lipid Arteriosclerosis's risk classification of treatment guidelines for dyslipidemia at 12 weeks from baseline
Time frame: 12 weeks
Percentage of subjects who reached LDL-C target
Percentage of subjects who reached LDL-C target according to Korean Society of Lipid Arteriosclerosis's risk classification of treatment guidelines for dyslipidemia at 24 weeks from baseline
Time frame: 24 weeks
Plan to share: Undecided — Undecided at this point
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewoong Pharmaceutical Co. LTD.